ECSP22049399A - C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer - Google Patents

C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer

Info

Publication number
ECSP22049399A
ECSP22049399A ECSENADI202249399A ECDI202249399A ECSP22049399A EC SP22049399 A ECSP22049399 A EC SP22049399A EC SENADI202249399 A ECSENADI202249399 A EC SENADI202249399A EC DI202249399 A ECDI202249399 A EC DI202249399A EC SP22049399 A ECSP22049399 A EC SP22049399A
Authority
EC
Ecuador
Prior art keywords
eso
treatment
cancer
cell containing
vector cell
Prior art date
Application number
ECSENADI202249399A
Other languages
English (en)
Inventor
Shinichiro Fujii
Tatsuya Okudaira
Ayaka AKIBA
Keisuke Ohsumi
Yasuhide MASUHARA
Original Assignee
Riken
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, Astellas Pharma Inc filed Critical Riken
Publication of ECSP22049399A publication Critical patent/ECSP22049399A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un objetivo de la presente invenci?n es dar a conocer una c?lula aAVC?NY?ESO?1 cl?nicamente aplicable que expresa NY?ESO?1 de manera estable para usar las c?lulas aAVC?NY?ESO?1 en el tratamiento de pacientes con c?ncer que expresa NY?ESO?1. La presente invenci?n brinda, por ejemplo, una c?lula de origen humano que comprende un polinucle?tido que codifica CD1d y un polinucle?tido que codifica NY?ESO?1 o un fragmento de ?sta, donde el polinucle?tido que codifica NY?ESO?1 o un fragmento de ?sta est? operativamente ligado a un promotor inducible.
ECSENADI202249399A 2019-12-02 2022-06-24 C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer ECSP22049399A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019217704 2019-12-02

Publications (1)

Publication Number Publication Date
ECSP22049399A true ECSP22049399A (es) 2022-08-31

Family

ID=76222293

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249399A ECSP22049399A (es) 2019-12-02 2022-06-24 C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer

Country Status (21)

Country Link
US (2) US11672851B2 (es)
EP (1) EP4071240A4 (es)
JP (1) JP7646213B2 (es)
KR (1) KR20220119030A (es)
CN (1) CN114787344A (es)
AR (1) AR120648A1 (es)
AU (1) AU2020394993A1 (es)
BR (1) BR112022010763A2 (es)
CA (1) CA3162277A1 (es)
CL (1) CL2022001459A1 (es)
CO (1) CO2022008738A2 (es)
CR (1) CR20220320A (es)
DO (1) DOP2022000108A (es)
EC (1) ECSP22049399A (es)
IL (1) IL293482A (es)
JO (1) JOP20220121A1 (es)
MX (1) MX2022006716A (es)
PE (1) PE20221463A1 (es)
PH (1) PH12022551334A1 (es)
TW (1) TW202134431A (es)
WO (1) WO2021112055A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
WO2025230010A1 (ja) * 2024-05-02 2025-11-06 国立研究開発法人理化学研究所 ＣＤ１ｄ導入前にＣＤ１ｄリガンドでインキュベートされた細胞

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
EP2441468B1 (en) * 2006-02-22 2020-01-08 Riken Immunotherapy by using cell capable of co-expressing target antigen and cd1d and pulsed with cd1d ligand
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
WO2008057795A2 (en) * 2006-10-27 2008-05-15 Temple University - Of The Commonwealth System Of Higher Education Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera
EP2112930B1 (en) * 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
US20110280895A1 (en) * 2008-11-28 2011-11-17 Riken IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
CN102905882A (zh) 2010-03-25 2013-01-30 3M创新有限公司 复合层
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
WO2013018778A1 (ja) 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP3328988A1 (en) 2015-07-31 2018-06-06 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
CA3050614A1 (en) * 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy

Also Published As

Publication number Publication date
US20230000965A1 (en) 2023-01-05
US20230330200A1 (en) 2023-10-19
CO2022008738A2 (es) 2022-07-19
IL293482A (en) 2022-08-01
BR112022010763A2 (pt) 2022-08-23
AU2020394993A1 (en) 2022-06-09
WO2021112055A1 (ja) 2021-06-10
CA3162277A1 (en) 2021-06-10
JOP20220121A1 (ar) 2022-05-23
AR120648A1 (es) 2022-03-09
EP4071240A1 (en) 2022-10-12
US11672851B2 (en) 2023-06-13
CN114787344A (zh) 2022-07-22
MX2022006716A (es) 2022-09-12
EP4071240A4 (en) 2024-01-17
CL2022001459A1 (es) 2023-02-24
CR20220320A (es) 2022-11-03
JPWO2021112055A1 (es) 2021-06-10
PH12022551334A1 (en) 2023-11-20
PE20221463A1 (es) 2022-09-21
TW202134431A (zh) 2021-09-16
DOP2022000108A (es) 2022-10-31
JP7646213B2 (ja) 2025-03-17
KR20220119030A (ko) 2022-08-26

Similar Documents

Publication Publication Date Title
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
MX2021009652A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
CO2017013432A2 (es) Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
NI201500057A (es) Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados
UY36332A (es) Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas
CL2022001459A1 (es) Célula vector adyuvante artificial con contenido de ny-eso-1 para el tratamiento del cancer
MX2024000276A (es) Analogo de peptido de oxintomodulina acilado.
CO2023016804A2 (es) Composiciones y métodos para el tratamiento de la pérdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de estereocilina
CL2020002650A1 (es) Enzimas quinureninasa humanas y sus usos
MX2019000235A (es) Eliminacion de la cistina mediada por enzimas humanas.
CL2020000069A1 (es) Mejora de las características del suelo con compuestos lactobionatos.
DOP2023000132A (es) Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
BR112012030821A2 (pt) vitronectina:fator de crescimento quimeras queratinócitos
MX2024003910A (es) Composiciones de administración de terapia génica y métodos para tratar la pérdida auditiva.
MX2024008804A (es) Arnbc, uso y metodo de preparacion para el mismo.
CO2021005872A2 (es) Composiciones y métodos para la estimulación ovárica controlada
CL2023000492A1 (es) Vector de poxviridae recombinante que expresa moléculas coestimuladoras
MX389222B (es) Metodos para mejorar la actividad de retinoides.
CO2018003759A2 (es) Tratamiento de la neuropatía periférica diabética usando células placentarias
MX2024008861A (es) Seleccion de pacientes para terapia de combinacion.
MX2023009999A (es) Metodos para reducir el riesgo de progresion del cancer de prostata.